Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
April 20, 2020 09:38 AM EDT
R&D

Piv­otal da­ta sug­gest clean safe­ty pro­file, po­ten­cy could set Idor­si­a's sleep­ing pill apart

Natalie Grover

Reporter

Swiss biotech Idor­sia, spun out of Acte­lion af­ter J&J wrapped up its $30 bil­lion takeover in 2017, is one step clos­er to the fin­ish …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times